Respiratory Tract Infections

Neumifil™ is a first-in-class mCBM40 being developed for the universal treatment of Influenza Virus (IFV), Respiratory Syncytial Virus (RSV) and COVID-19. Neumifil™ has the potential to revolutionise the treatment of Respiratory Tract Infections (RTIs) by providing clinicians with the opportunity to offer their patients pan-viral protection, thus overcoming the limitations of vaccines and other therapeutic approaches.

Neumifil is being developed as an easy to use self-administered intranasal spray, to stop respiratory viruses at their site of infection into the body – the nasal lining. This is a universal approach to respiratory tract infections, by blocking viral entry through the lining of the nose. This stops systemic infection and the virus gaining access to the lungs and becoming entrenched. As glycans on the nose linings are being targeted, it is less likely resistance to Neumifil will develop, compared with approaches such as antibodies which target elements of the virus, such as the spike protein in SARS-COV-2. Neumifil effectively closes the nose as a port of entry for respiratory viruses, providing pre and post exposure prophylaxis.

Priority targets for this spray would be those at high-risk from respiratory viral infection including front-line health professionals, the elderly (especially those in care homes), and also those who are obese, diabetic or are more susceptible to respiratory infections including seasonal ‘flu, such as people with chronic obstructive pulmonary disease and asthma.

Neumifil has been designed to have easily scalable manufacture, using E. coli, producing a hexavalent single protein, delivering a low cost of goods. Its clinical process and supply chain have already been established with an experienced commercial CDMO. Eight patent families protect Pneumagen’s intellectual property, including platform, product and composition patents, both granted and pending.

 

 

Nasal inhalation device prototype for delivery of Neumifil

Pipeline Progress

When administered intranasally in preclinical models, Neumifil™ has demonstrated prevention, treatment and post-exposure prophylaxis of influenza virus infection and Respiratory Syncytial Virus (RSV) infection, with no observed toxicity. It is also in preclinical development for COVID-19. First-in-man clinical trials will commence in mid-2021.

Neumifil™ will be administered intranasally. It will be developed for those at high-risk of RTI infections such as the elderly, immuno-compromised diabetics, and those with underlying lung disease such as asthma and COPD.

Pneumagen is not recruiting volunteers for its planned clinical studies at this time. This is a line of clinical research we are following and we will make announcements when we are ready to start recruitment.